CompletedPhase 2

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

United States196 participantsStarted 2018-11-15

Plain-language summary

The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI) * Diagnosed with cellulitis/erysipelas, major cutaneous abscess, or wound infections Exclusion Criteria: * Uncomplicated skin infections * Severe sepsis or septic shock * ABSSSI solely due to Gram-negative pathogens * Prior systemic antibiotics within 96 hours of randomization

What they're measuring

Early Clinical Response at the Early Assessment Visit (ITT Population)

Timeframe: 48 to 72 hours after the start of study drug

Trial details

NCT IDNCT03747497

SponsorMicuRx

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-03-26

Results submitted2021-04-06

View on ClinicalTrials.gov More Skin Diseases, Bacterial trials